Jasper Therapeutics
JSPR
53 hedge funds and large institutions have $83.5M invested in Jasper Therapeutics in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
4% more funds holding
Funds holding: 51 → 53 (+2)
2% more capital invested
Capital invested by funds: $81.9M → $83.5M (+$1.62M)
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$3.56M |
| 2 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$3.18M |
| 3 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
+$1.69M |
| 4 |
OCAM
Owl Creek Asset Management
New York
|
+$1.52M |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
|
-$4.75M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$4.57M |
| 3 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
-$2.1M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$938K |
| 5 |
Goldman Sachs
New York
|
-$651K |
JSPR Hedge Fund Activity: Q1 2021 in Review
53 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2021, worth a combined $83.5M — up 2% from $81.9M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new JSPR positions and 7 closed out — a net gain of 3 holders — while 11 added to existing stakes and 13 trimmed.
The largest buyer was Shaolin Capital Management, adding an estimated $3.56M. The largest seller was P. Schoenfeld Asset Management (PSAM), exiting entirely with an estimated $4.75M sold.
- 53 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2021, up from 51 in Q4 2020.
- Funds reported $83.5M of Jasper Therapeutics stock for Q1 2021, up 2% quarter-over-quarter.
- 10 funds opened new Jasper Therapeutics positions in Q1 2021 and 7 closed out, a net change of +3 holders.
- The largest Jasper Therapeutics buyer in Q1 2021 was Shaolin Capital Management, an estimated $3.56M added.
- The largest Jasper Therapeutics seller in Q1 2021 was P. Schoenfeld Asset Management (PSAM), an estimated $4.75M sold.
Based on aggregated 13F filings for Q1 2021.